Navigation Links
Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
Date:12/21/2010

SAN DIEGO, Dec. 21, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Jack Lief, Arena's President and Chief Executive Officer, will host a conference call and webcast tomorrow, Wednesday, December 22, 2010, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to provide an update following the completion of an end-of-review meeting with the US Food and Drug Administration (FDA) for the lorcaserin New Drug Application (NDA).

The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Lorcaserin" conference call. The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States following FDA approval of the New Drug Application for lorcaserin.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company.

Forward-Looking Statements Certain statements in this press release are forward-looking
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... , Sept. 20, 2014 /CNW/ - The issue: Mylan Pharmaceuticals ... all lots of its Mylan-Nitro Spray 0.4 mg/metered dose due ... of the pump component. A missing "dip ... nitroglycerin to the patient. This defect may lead patients to ... are unable to access it. Not receiving nitroglycerin could place ...
(Date:9/19/2014)... 2014 Medical science liaisons (MSLs) play ... opinion leaders (KOLs) who can provide essential insights ... nature of the MSL function, the changing regulatory ... landscape for creating and maintaining KOL and physician ... oversight responsibility for the MSL function is increasingly ...
(Date:9/19/2014)... NEW YORK , Sept. 19, 2014 ... claims against the board of directors of PDL BioPharma, ... ) concerning whether the board has breached its fiduciary ... On September 16, 2014, the Company disclosed: ... its independent registered accounting firm, Ernst & Young LLP ...
Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... 7, 2011 Adeona Pharmaceuticals, Inc. (AMEX: AEN ... system diseases, announced today that it has executed an agreement ... at approximately $2.0725 per share to a new institutional investor ... proceeds. The investor will also receive warrants to purchase approximately ...
... Graymark Healthcare Inc. (NASDAQ: GRMH ), ... and an innovator in comprehensive care for obstructive sleep ... resupply shipments in the first quarter of 2011.  Resupply ... in what is typically the slowest quarter of the ...
Cached Medicine Technology:Adeona to Raise $3.5 Million in Registered Direct Offering 2Adeona to Raise $3.5 Million in Registered Direct Offering 3Graymark Resupply Orders Reach Record Levels in Q1 2011, Up 107% Year-Over-Year 2Graymark Resupply Orders Reach Record Levels in Q1 2011, Up 107% Year-Over-Year 3
(Date:9/20/2014)... News) -- As flu season approaches, the best way ... a flu shot and a checkup, according to an ... can vaccinate people against the flu, and also address ... stores may provide flu shots for their customers, but ... Parada, medical director of infection prevention and control for ...
(Date:9/20/2014)... 20, 2014 As concerns surrounding ... in gynecological surgeries continue to grow, Bernstein ... announced plans to end coverage for uterine morcellation. ... last month, Harrisburg, Pennsylvania-based Capital BlueCross will end ... The insurer said its decision was prompted by ...
(Date:9/20/2014)... Traditionally dentists have advised their patients against drinking coffee and ... re-visiting that advice and changing his stance after considering two ... on oral health. “There’s good news and great news,” says ... in protecting against gum disease, and red wine can help ... from the September 2014 issue of Boston University School ...
(Date:9/20/2014)... NY (PRWEB) September 20, 2014 Earlier this ... their customers may have had their credit card information pilfered ... year, spawning a slew of headline articles like this ... weren’t the only eye opening numbers. , “Most people ... stolen, almost like it’s a way to score a game,” ...
(Date:9/20/2014)... September 20, 2014 The Arizona Advanced ... (MCC) is celebrating National Manufacturing Day by opening its ... machining, processing and additive manufacturing labs will be offered ... 2014 at MCC’s Southern and Dobson campus (1833 W. ... southeast Lot D. , The AzAMI at MCC was ...
Breaking Medicine News(10 mins):Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
... up a big sweat to reap the healing benefits ... low-intense exercise program can reduce depression symptoms and boost ... "The power of physical activity to raise the spirits ... Heart and Stroke Foundation researcher Dr. Jocelyn Harris told ...
... German researchers reported that alcohol consumption and cigarette smoking ... in high school students. Coffee drinking and physical inactivity ... the first to investigate modifiable risk factors for different ... early in Headache , a journal published by ...
... of Public Health (HSPH) have found that children and ... promoting smoke-free public places have significantly lower levels of ... living in counties with no smoke-free laws. The ... smoke-free laws had 39% lower prevalence of cotinine in ...
... in the department of biochemistry and organic chemistry at ... year,s recipient of the Georg Charles de Hevesy Nuclear ... profession. Lngstrm was presented the award by SNMan international ... 5𔃇, in Salt Lake City, Utah. In ...
... ... 26th of June 2010. The funds will go to the charities of Live and Cudeca. ... (PRWEB) June 5, 2010 -- On June ... the 4B business networking group a charity skydiving event in Seville. , , ,The collected funds ...
... The combination of two different chemotherapies and a previously ... effective against advanced melanoma, according to results disclosed in ... of the American Society of Clinical Oncology (ASCO) in ... important about the treatment of melanoma," said John M. ...
Cached Medicine News:Health News:Non-intense physical activity to reduce depression and boost recovery of stroke patients 2Health News:Non-intense physical activity to reduce depression and boost recovery of stroke patients 3Health News:Alcohol use and smoking are associated with headaches in high schoolers 2Health News:Smoke-free air laws effective at protecting children from secondhand smoke 2Health News:Bengt Roland Långström receives SNM's 2010 Georg Charles de Hevesy Nuclear Pioneer Award 2Health News:Combination treatment regimen not effective against advanced melanoma 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: